Catalog No.
DHB94408
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
VH-VH'-VH
Clonality
Monoclonal
Target
TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1, ALB, Albumin
Concentration
0.52 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01375 & P02768
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, ATN-103, CAS: 1167985-17-2
Clone ID
Ozoralizumab
Effects of immunotherapy on isolated optic neuritis associated with ozoralizumab, a novel anti-tumor necrosis factor α NANOBODY® compound: A case report., PMID:40486722
New anti-TNF biologics in RA: What is new and what is old?, PMID:40180877
Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: A post hoc analysis of the OHZORA trial., PMID:40139716
Rapid improvement of rheumatoid arthritis symptoms with ozoralizumab: a case of progress monitored by musculoskeletal ultrasonography., PMID:39969218
Research trends in the use of nanobodies for cancer therapy., PMID:39922288
Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis., PMID:39869270
Correction: Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis., PMID:39578021
Acute heart failure with reduced ejection fraction following ozoralizumab in a patient with rheumatoid arthritis: A case report., PMID:39242351
Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis., PMID:39179257
Development of a novel bacterial production system for recombinant bioactive proteins completely free from endotoxin contamination., PMID:39161731
Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy., PMID:39083975
Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis., PMID:38814660
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab., PMID:38584236
A pivotal decade for bispecific antibodies?, PMID:38465614
[Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 mg Syringes for S.C. Injection), the first Nanobody® compound in Japan]., PMID:37914330
Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis., PMID:37909264
Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis., PMID:37804232
Isolation and Characterization of Single-Domain Antibodies from Immune Phage Display Libraries., PMID:37679618
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis., PMID:37431762
Inducer-free recombinant protein production in Trichoderma reesei: secretory production of endogenous enzymes and heterologous nanobodies using glucose as the sole carbon source., PMID:37208691
Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor., PMID:37185766
Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation., PMID:37122706
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials., PMID:37055803
Ozoralizumab: First Approval., PMID:36509938
Antibodies to watch in 2023., PMID:36472472
A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis., PMID:36302840
Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)., PMID:36201360
Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial)., PMID:36197757
Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis., PMID:35729713
Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG., PMID:35273620
Clinical impact of serum proteins on drug delivery., PMID:22155554